Sugi Predict

Sugi Predict / Compounds / SCHEMBL3228891

SCHEMBL3228891

SCHEMBL3228891

O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COC(=O)c1cc(O)c(O)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SERPINE1 P05121 6/20 0.55
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PTPN11 Q06124 1/20 0.46
▸ ESR1 P03372 2/20 0.43
▸ AKR1C4 P17516 1/20 0.41
▸ AKR1C3 P42330 1/20 0.41
▸ AKR1C2 P52895 1/20 0.41
▸ AKR1C1 Q04828 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ TYR P14679 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ XDH P47989 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20578289 1.00 SERPINE1 (0.55) SERPINE1PTPN2PTPN1PTPN11ESR1
Gallic Acid SCHEMBL27999669 0.95 SERPINE1 (0.50) SERPINE1PTPN2PTPN1PTPN11ESR1
SCHEMBL3982817 0.87 SERPINE1 (0.57) SERPINE1PTPN2PTPN1PTPN11ESR1
SCHEMBL28219841 0.87 SERPINE1 (0.57) SERPINE1PTPN2PTPN1PTPN11ESR1
SCHEMBL16585686 0.84 SERPINE1 (0.59) SERPINE1PTPN2PTPN1PTPN11ESR1
SCHEMBL18585793 0.84 SERPINE1 (0.59) SERPINE1PTPN2PTPN1PTPN11ESR1
SCHEMBL18585722 0.82 SERPINE1 (0.58) SERPINE1PTPN2PTPN1PTPN11ESR1
SCHEMBL15303745 0.82 SERPINE1 (0.58) SERPINE1PTPN2PTPN1PTPN11ESR1
Propyl Gallate SCHEMBL27615329 0.81 ESR1 (0.52) SERPINE1ESR1AKR1C4AKR1C3AKR1C2
SCHEMBL18585433 0.81 SERPINE1 (0.59) SERPINE1PTPN2PTPN1PTPN11ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119386099-A Pharmaceutical composition and application thereof 西藏甘露医药科技有限责任公司 2025-02-07 — — CN claimed
CN-114748496-A Gemcitabine sensitizers 兰州大学第二医院 2022-07-15 — — CN claimed
US-20170014362-A1 ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE CHATTERJEE SUBROTO (US) 2017-01-19 — — US claimed
US-9376369-B2 Anti-cholesterolemic compounds and methods of use CHATTERJEE SUBROTO (US) 2016-06-28 — — US claimed
US-20140031304-A1 ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE CHATTERJEE SUBROTO (US) 2014-01-30 — — US claimed
US-8492351-B2 Anti-cholesterolemic compounds and methods of use NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2013-07-23 — — US claimed
EP-2094085-A2 ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE The Johns Hopkins University (US) 2009-09-02 — — EP claimed
WO-2008080162-A2 ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE THE JOHNS HOPKINS UNIVERSITY (US) 2008-07-03 — — WO claimed
EP-0654479-B1 Esculetin derivatives and method for manufacture thereof, use thereof, and pharmaceutical composition KUREHA CHEMICAL IND CO LTD (JP) 2000-03-15 — — EP claimed
US-5266319-A Tannin derivatives and their use for treatment of hypertension NATIONAL SCIENCE COUNCIL (TW) 1993-11-30 — — US claimed
JP-5294835-A — — None — — JP disclosed
US-20250275997-A1 Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester BONAFIDE HEALTH, LLC 2025-09-04 — — US disclosed
US-12303524-B2 Compositions comprising S-adenosylmethionine and a gallic acid ester MSI-195 HOLDINGS, LLC (US) 2025-05-20 — — US disclosed
CN-119386099-A Pharmaceutical composition and application thereof 西藏甘露医药科技有限责任公司 2025-02-07 — — CN disclosed
CN-115433391-A Carbon material-loaded silicon dioxide hybrid filler and preparation method and application thereof 浦林成山（山东）轮胎有限公司 2022-12-06 — — CN disclosed
EP-0654479-B1 Esculetin derivatives and method for manufacture thereof, use thereof, and pharmaceutical composition KUREHA CHEMICAL IND CO LTD (JP) 2000-03-15 — — EP disclosed
CN-1133070-A Reagent TRACE SCIENT PTY LTD (AU) 1996-10-09 — — CN disclosed
US-5266319-A Tannin derivatives and their use for treatment of hypertension NATIONAL SCIENCE COUNCIL (TW) 1993-11-30 — — US disclosed
US-5266319-A Tannin derivatives and their use for treatment of hypertension NATIONAL SCIENCE COUNCIL (TW) 1993-11-30 — — US disclosed
JP-H05294835-A ANTIHYPERTENSIVE MEDICINE NATL SCI COUNCIL 1993-11-09 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275997-A1 Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester BHMT2, BHMT, MAT1A SERPINE1 2043/4885PTPN2 4835/4885PTPN1 4817/4885
US-20140031304-A1 ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE CETP, NPC1L1, HMGCR SERPINE1 1091/4885PTPN2 3691/4885PTPN1 4087/4885
US-12303524-B2 Compositions comprising S-adenosylmethionine and a gallic acid ester BHMT2, BHMT, MAT1A SERPINE1 2043/4885PTPN2 4835/4885PTPN1 4817/4885
US-20170014362-A1 ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE CETP, NPC1L1, HMGCR SERPINE1 1091/4885PTPN2 3691/4885PTPN1 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.